Uric acid induces liver fibrosis through activation of inflammatory mediators and proliferating hepatic stellate cell in mice
Arfian N., Sari D.C.R., Tranggono U., Romi M.M., Setyaningsih W.A.W., Soetoko A.S.
Abstract
Introduction: Uric acid is associated with cardiometabolic risk factor and severity of liver damage. The mechanism of uric acid inducing liver damage is still elusive. This study elucidates the development of liver fibrosis under hyperuricemia. Methods and Materials: Hyperuricemia model was performed in male Swiss Webster mice. Intraperitoneally injection of uric acid (125mg/kg body weight) was done for 7 and 14 days (UA7 and UA14 groups). Meanwhile, the UAL groups were injected with uric acid and followed by the administration of allopurinol (UAL7 and UAL14 groups). On the due date, mice were sacrificed, and liver was harvested. Uric acid, SGOT, SGPT, and albumin level were measured from the serum. The mRNA expression of TLR4, MCP1, CD68, and collagen1 were assessed through RT-PCR. Liver fibrosis was quantified through Sirius red staining, while the number of hepatic stellates cells (HSCs) and TLR4 were assessed through IHC staining. Results: Uric acid induction for 7 and 14 days stimulated an increase of both SGOT and SGPT serum levels. Followed by enhanced inflammatory mediators: Toll-like receptor-4 (TLR4), Monocyte Chemoattractant Protein-1 (MCP-1) and Cluster of Differentiation 68 (CD68) mRNA expression in the liver (p<0.05). The histological findings showed that the UA7 and UA14 groups had higher liver fibrosis scores (p<0.05), collagen I mRNA expression (p<0.05), and the number of HSCs (p<0.05) compared to Control group. Administration of allopurinol showed amelioration of uric acid and liver enzymes levels which followed by inflammatory mediators, liver fibrosis and collagen1, and hepatic stellate cells significantly. Conclusion: Therefore, uric acid augmented the liver fibrosis by increasing the number of hepatic stellate cells.
Association of the serum uric acid level with liver histology in biopsy-proven non-alcoholic fatty liver disease
Ge Y., Huang Q., Liu S., Yu J., Zhang X.
Allopurinol reverses liver damage induced by chronic carbon tetrachloride treatment by decreasing oxidative stress, TGF-β production and NF-κB nuclear translocation
Aldaba-Muruato L.R., Moreno M.G., Muriel P., Shibayama M., Tsutsumi V.
Allopurinol reduces antigen-specific and polyclonal activation of human T cells
Albareda M.C., Alvarez M.G., Bertocchi G.L., Laucella S.A., Lococo B., Perez-Mazliah D., Perez-Mazliah D., Petti M., Viotti R.J.
Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis
Charron S., Couillin I., Couillin I., Couillin I., Fick L., Gasse P., Girre S., Lagente V., Petrilli V., Quesniaux V.F.J., Riteau N., Ryffel B., Tschopp J.
Liver fibrosis: Cellular mechanisms of progression and resolution
Henderson N.C., Iredale J.P.
Toll like receptor 2 knock-out attenuates carbon tetrachloride (CCl 4)-induced liver fibrosis by downregulating MAPK and NF-κB signaling pathways
Chen S., Gu J., Hu T., Ji L., Liu X., Peng X., Tang W., Wu W., Xue R., Zhang S.
The Cellular Basis of Hepatic Fibrosis – Mechanisms and Treatment Strategies
Flier J.S., Friedman S.L., Friedman S.L., Underhill L.H.
Cellular Sources of Extracellular Matrix in Hepatic Fibrosis
Wells R.G.
Hepatic stellate cell immunodetection and cirrhotic evolution of viral hepatitis in liver allografts
Fiel I.M., Guido M., Leandro G., Rugge M., Rugge M., Thung S.N.
Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway
Chen W., Fu C., Han R., Lu Y., Xiao J., Ye Z., Zhang X.-L.
Jiang B., Yang W., Li C., Zhao Y., Lai Y., Chen H., Li X., Qiu J., Weng Y., Chen Y.
International Journal of Molecular Sciences
Xi Q., Chen T., Luo J., Sun J., Chen X., Liu J., Zhang Y.
International Journal of Molecular Sciences
Wu C.-H., Sun Z.-J., Li C.-H., Chang Y.-F., Lu F.-H., Wu J.-S., Chou Y.-T., Chang C.-J., Yen P.-C., Yang Y.-C.
Journal of Clinical Medicine
Xu Y., Lu W., Huang L., Zhou L., Peng W., Wang S., Chen W., Xu H., Liu N., He X., Xu W., He X., Wang Y., Xu B.
Biochemical and Biophysical Research Communications
Wan H., Shen J., Chen X., Song C., Yu G., Duan H., He Y., Zhang R., Jiang Y.
Frontiers in Endocrinology
Hu C.-C., Lin C.-L., Chien C.-H., Xie C.-H., Chen L.-W.
Journal of Personalized Medicine
Liu D., Qin X., Chen R., Zhang Q., Chen L., He X., Li Z.
Science and Technology of Food Industry
Wu Z., Lu H., Zhang H., Li L.
Microbiome Research Reports
Yuan Z., Li H., Wang C., Chen F., Shi X., Hou L., Geng Z., Xue F.
Briefings in Bioinformatics
Ren F., Mao Y., Yu X., Zhang X., Hou B., Zhang X., Fu Y., Xie Z., Wang X., Deng L., Ma M.
Journal of Applied Toxicology
